NPS RADAR April 2008

Title Why read this
Fentanyl lozenges (Actiq) for breakthrough cancer pain Information on use of fentanyl lozenges (Actiq) for breakthrough cancer pain, including safety concerns and dosing issues.
Varenicline (Champix) for smoking cessation Review of varenicline (Champix) for smoking cessation, including adverse effects, treatment efficacy, and drug interactions.
Paliperidone (Invega) for schizophrenia Information on use of paliperidone (Invega) for schizophrenia, including safety and dosing issues.
Pioglitazone Information on use of pioglitazone (Actos) for type 2 diabetes mellitus, including safety and dosing issues.
Brief item: methylphenidate (Ritalin LA): a second controlled-release formulation PBS listed for attention deficit hyperactivity disorder A second controlled-release formulation of methylphenidate (Ritalin LA) was listed on the PBS to be prescribed for patients aged 6 to 18 years inclusive for attention deficit hyperactivity disorder (ADHD).
Brief item: smaller dose volume of influenza vaccine PBS listed for children aged 6–35 months A smaller dose volume (0.25 mL) of influenza vaccine has been PBS listed for children aged 6-35 months who are at risk of adverse outcomes from lower respiratory tract infections.
Brief item: terbinafine authority listed for fungal infections in Aboriginal and Torres Strait Islander peoples The authority listing for terbinafine 250 mg tablets was extended o allow the treatment of Aboriginal and Torres Strait Islander peoples with a dermatophyte infection that has not responded to topical treatment.
NPS RADAR April 2008 NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.